Biological markers for non-celiac gluten sensitivity: a question awaiting for a convincing answer

Enzo Ierardi1, Giuseppe Losurdo1, Domenico Piscitelli2, Floriana Giorgio1, Annacinzia Amoruso1, Andrea Iannone1, Mariabeatrice Principi1, Alfredo Di Leo1

1Section of Gastroenterology, Department of Emergency and Organ Transplantation, University of Bari “Aldo Moro”, Italy
2Section of Pathology, Department of Emergency and Organ Transplantation, University of Bari “Aldo Moro”, Italy

ABSTRACT

Non Celiac Gluten Sensitivity (NCGS) is characterized by immunological, morphological or symptomatic manifestations precipitated by gluten ingestion in individuals without celiac disease (CD). The most important challenge in NCGS is the diagnosis, currently based only on clinical observation. The “Salerno criteria” have been pointed out to achieve a reliable diagnosis even if they lack immediacy and practicality, thus making questionable patient’s adherence. Therefore, biological indicators supporting the clinical diagnosis of NCGS are advisable. For these reasons, many attempts have been performed in order to identify possible serological, immunological, histopathological, immunohistochemical and pathophysiological aspects characterizing this condition with the aim of using them for diagnostic purposes. In the present narrative review, we carried out an update of the current scenario of potential markers of NCGS. The main fault of available studies is that, in most cases investigations have been pointed out towards molecules, which cannot be searched in the current laboratories of clinical analysis. Therefore, the matter has been confined within basic research. Additionally, in these studies, sensitivity and specificity of biological markers were not computable. This is a relevant limit, since an ideal test for NCGS should have a good discriminative power against both CD and other causes of microscopic enteritis. Until now, serological tests have failed, while the search for a soluble marker indicative of activation of innate immune system as well as immunohistochemistry could be the promising bases for the development of appropriate investigations in the future.

Keywords: Gluten sensitivity, Marker, Diagnosis, Cytokines, Immunohistochemistry.

Introduction

The concept of Non Celiac Gluten Sensitivity (NCGS) has been developing in recent years until the recognition of this condition as a gluten related disease with peculiar characteristics (1). According to the Oslo definition (2), it consists of “a variety of immunological, morphological, or symptomatic manifestations that are precipitated by the ingestion of gluten in individuals in whom celiac disease has been excluded”. Gastrointestinal manifestations, such as diarrhea, abdominal pain and bloating are the dominant features. However, NCGS may display headache, fatigue, osteopenia or skin manifestations. NCGS shows peculiar clinical features in comparison to celiac disease (CD), such as the onset of symptoms shortly after wheat ingestion followed by a prompt response to gluten free diet. Simultaneously, villous atrophy and serological markers of CD are absent. The pathogenesis of NCGS is almost obscure. A selective involvement of innate immunity has been invoked (3) as well as an immune response to wheat constituents other than gluten (amylase-trypsin inhibitors) has been hypothesized (4). The most important challenge in NCGS is the diagnosis. Currently, the diagnosis is based only on clinical observation and relies on the exclusion of CD and other possible causes of diarrhea and abdominal...
204 Biological markers for non-celiac gluten sensitivity

Pain. In this setting, a subjective complaint of a relationship between symptoms and gluten ingestion, which in several reports reaches a prevalence of 10.6%, may be a confounding factor (5). It is evident that this value cannot be a realistic percentage and is presumably due to the so-called "nocebo effect". On these bases, the “Salerno criteria” have been pointed out in order to achieve a more solid diagnosis (6). Accordingly, diagnostic protocol encloses two steps: an initial evaluation of a gluten free diet followed by a double blind placebo controlled challenge with crossover. During this phase, symptom evaluation is guided by a Gastrointestinal Symptom Rating Scale filled out by patients. This protocol has been demonstrated to reach a high level of evidence for diagnosing NCGS. For example, it has been shown that only the 14% of self-reported gluten sensitivity is really suffering from this condition (7). Nevertheless, the whole procedure requires nine weeks and, for this reason, it lacks immediacy and practicality and patient adherence may be questionable. Therefore, biological indicators supporting the clinical diagnosis of NCGS are advisable. Consequently, the aim of the present narrative review was to give an updated scenario of potential markers of NCGS. For this reason, we entered in the PubMed database the following key words: non celiac gluten sensitivity, biomarker, serology, anti-gliadin antibodies, intestinal permeability, toll like receptors, cytokine, interleukin, immunohistochemistry, intraepithelial lymphocytes and diagnosis. Since the literature data were extremely heterogeneous, we were unable to perform a systematic review, therefore we planned to carry out a narrative review. The selection process of the papers selected for this review is summarized in Figure 1.

Serology

As above reported, NCGS differs from CD for the absence of typical auto-antibodies, such as anti-transglutaminase or anti-endomysium. Nevertheless, some reports showed that about half of the patients with NCGS experienced positivity for native IgG anti-gliadin antibodies. At this regard, Volta et al. demonstrated in 2012 a value of prevalence of the 56.4% of positive IgG anti-gliadin (8) and comparable percentages were confirmed by successive cohort studies (9, 10). Interestingly, the adherence to gluten free diet was demonstrated to allow negativity of such antibodies in the 93.2% of cases (11). Finally, even in pediatric age a noticeable positivity for IgG anti-gliadin antibodies (66%) was observed (12).

Additionally, objective markers of systemic immune activation and gut epithelial cell damage in individuals with sensitivity to wheat in the absence of CD have been demonstrated (13). In detail, these markers are

![Figure 1. Flowchart summarizing the process of Pubmed search and articles selection.](image)
represented by increased levels of soluble CD14, lipopolysaccharide-binding protein and antibody reactivity to microbial antigens, indicating systemic immune activation (IgM anti-Endotoxin Core, which is a hint of B cell response towards microbial antigens). These findings may encourage additional researches aimed to assess potential biological indicators of NCGS.

Cytokines and Immunology

The investigation of soluble mediators of inflammation, in particular cytokines (chemokines and interleukines – IL) and immune system cells constitute a relevant field of research about NCGS. Indeed, there is strong evidence that the involvement of innate immune system is essential in NCGS, while acquired immunity has a negligible value. This aspect has been invoked to explain the well-known negativity of CD serological markers in this condition. Therefore, several studies have been pointed out on the evaluations of possible markers of native immunity in NCGS. Two basic studies from Sapone et al. (14, 15) dearly supported this hypothesis by showing an increase of mRNA codifying for toll like receptors (TLR)-2 and claudin 4. TLRs are receptors activated by nonself-antigens during innate immune response. Claudin 4 is a member of a family of molecules which are integral components of tight junctions. Nevertheless, such results have not been replicated in successive studies. Picarelli et al. (16) found that immunohistochemical expression of TLR2 in duodenal mucosa of NCGS was comparable to that of CD and controls. In our experience, mRNA-TLR2 had similar levels in subjects with CD and controls and their expression failed to predict NCGS development in a cohort of patients with microscopic enteritis (17). Additionally, a satisfactory predictive performance was observed for interferon gamma and tissue transglutaminase 2 mucosal expression. Recently, the levels of CD14 lymphocytes and lipopolysaccharide binding protein have been shown to be higher in NCGS compared to healthy controls and CD (13). These biological markers are indicators of innate immune activation against bacterial antigens, thus confirming the hypothesized original pathogenetic pathway of this condition. This finding did not agree with the experience of Di Sabatino et al. (18), who failed to find differences in the supernatants of ex vivo cultured duodenal samples of patients with self-reported NCGS in the expression of cytokines characterizing innate (IL6, IL1, IL23, IL27, IL32 and tumor necrosis factor alpha) and adaptive immunity (IL4, IL5, IL10, IL13, IL17A, interferon gamma). However, this study has the remarkable limit due to the enrollment of patients with self-reported gluten sensitivity.

Another approach to cytokine analysis in NCGS has been based on the provocative stimulus of gluten on immune cells both in vivo and in vitro and interesting, even if preliminary, data have been obtained. A gluten challenge in patients with NCGS induced an increase in intraepithelial lymphocytes (IELs) and mucosal interferon gamma, while no change in heat shock protein 27 and 70 was recorded (19). Similarly, gliadin was not able to upregulate some markers of basophil activation such as CD63 and CD203c in duodenal biopsy cultures (20). Finally, the exposure to gluten induced the secretion of CXCL10 chemokine by peripheral mononuclear blood cells of patients with NCGS (21, 22).

Histopathology and Immunohistochemistry

NCGS is characterized by a normal duodenal histological picture (Marsh 0 stage) as well as by an increase of IELs above 25/100 enterocytes with a normal villous architecture (Marsh 1 stage). Therefore, NCGS could be acknowledged as a cause of duodenal lymphocytosis/microscopic enteritis (23, 24). Since the first reports of NCGS, CD3 duodenal staining for IELs showed that this condition exhibited intermediate count values between controls and CD (14). Furthermore, we found that duodenal lymphocytosis of 15-25 IELs/100 enterocytes may be a risk factor for the evolution towards NCGS in a group of patients with microscopic enteritis (17). Additionally, a satisfactory predictive performance was observed for interferon gamma and tissue transglutaminase 2 mucosal expression. Villanacci et al. suggested that a linear T-lymphocyte infiltration (hallmarked by CD3 staining) in the lamina propria could characterize NCGS (26). However, this finding was observed in a single-center experience and involved about the 78.5% of the patients. Eosinophilia in the lamina propria has also been proposed as a possible peculiar NCGS feature (10, 16). Our latest study demonstrated that the immunohistochemistry for CD4 (a marker of T-helper lymphocytes) in the lamina propria had a sensitivity of 100% and a specificity of 90% to discriminate between NCGS and CD as well as
a sensitivity of 87.5% and a specificity of 85% in differentiating between healthy controls and NCGS (27). Indeed, CD8+ cell infiltration in the lamina propria of NCGS was intermediate between controls and CD. Moreover, CD117 staining allowed detecting higher levels of positive cells in NCGS than in controls and CD. In this case, a value of 134 cells/mm² discriminated between NCGS versus CD and controls with a sensitivity of 75% and a specificity of 55% (27). Since CD117 is a staining which could identify mast cells, this finding could support the results of some reports claiming that an allergic sensitivity to food allergens other than wheat may play a role in NCGS (28, 29). At this regard, however, it should be highlighted that mast cells are directly involved in all gluten related disorders, since gliadin is able to induce their degranulation with a consequent inflammatory cytokine production (30).

Finally, a very interesting finding was revealed by the study of rectal biopsy samples of patients with NCGS. Indeed, an increase in interferon gamma producing type-1 innate lymphoid cells with a characteristic CD45(+) T-bet(+), CD56(-), NKP44(-), and CD117(-) pattern was observed. Of interest, this aspect was reverted by a gluten free diet (31).

**Pathophysiology**

The determination of intestinal permeability by means of lactulose/mannitol test has been poorly investigated in NCGS. This investigation involves the administration of a solution containing lactulose and mannitol; an enhanced permeability is indicated by an increase in lactulose and a decrease in mannitol absorption (32). An experience from Sapone et al. performed in 26 NCGS subjects, 42 CD patients and 39 healthy gluten tolerant controls, failed to demonstrate an alteration of intestinal permeability in NCGS (14). On the other hand, further evidences showed opposite results. Hollon et al. (33) measured permeability by transepithelial electrical resistance in cultured duodenal biopsy samples and displayed that gliadin increased intestinal permeability in NCGS more than in CD patients and healthy subjects. Furthermore, fatty acid binding protein 2, a surrogate marker of epithelial damage and permeability, was found higher in NCGS than in controls (13). Therefore, the debate about intestinal permeability in NCGS is still open, since there are heterogeneous data.

Finally, oral gluten provocation test has been tested in a single experience (16). Such investigation consists in the application of gluten containing patches on the oral mucosa. The test is positive if mucosal hyperemia, edema, blisters or burning occur in the mouth. The test was positive in the 75% of NCGS, statistically higher than CD both under gluten containing (15%) and free diet (25%). The test did not give a positive result in healthy controls. This finding, when confirmed in a multicenter study involving a large population sample, could be a simple and effective test to diagnose NCGS.

**Conclusion**

Despite many attempts and promising preliminary indications, at the moment no biological marker has shown an adequate reliability for the diagnosis of NCGS, which remains based on clinical exclusion criteria. Therefore, clinical suspicion is still fundamental in this field and double blind placebo controlled challenge with crossover remains the diagnostic “gold standard”. However, it shows obvious limitations related to the long duration and the lack of practicality. Therefore, a biological marker for NCGS may be very advantageous. Advantages and disadvantages of currently available diagnostic potential investigations have been summarized in table 1.

The main flaw in the studies aimed to identify a reliable marker is that, in most cases, investigations have been pointed out towards molecules which cannot be searched in the current laboratories of clinical analysis. Therefore, the matter has been confined within basic research. Additionally, in most studies, sensitivity and specificity of biological markers were not computable. This is a relevant limit, since an ideal test for NCGS should have a good discriminative power against both CD and other causes of microscopic enteritis. Until now, serological tests have failed except for native IgG anti-gliadin antibodies, which are present, however, only in the 50% of patients (34, 35). Therefore, the search for a soluble marker indicative of activation of innate immune system as well as immunohistochemistry peculiarities could be the promising bases for the development of appropriate investigations in the future. However, the right road seems to be still long.
Conflict of interests

The authors declare that they have no conflict of interest.

References

1. Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, et al. Non-Celiac Gluten sensitivity: the new frontier of gluten related disorders. Nutrients 2013;5:3839-53.
2. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013;62:43-52.
3. Caio G, Riegler G, Patturelli M, Facchiano A, DE Magistris L, Sapone A. Pathophysiology of non-celiac gluten sensitivity: where are we now? Minerva Gastroenterol Dietol 2017;63:16-21.
4. Zavallos VF, Raker V, Tenzer S, Jimenez-Calvente C, Ashfaq-Khan M, Rüssel N, et al. Nutritional Wheat Amylase-Trypsin Inhibitors Promote Intestinal Inflammation via Activation of Myeloid Cells. Gastroenterology 2017;152:1100-13.e12.
5. Golley S, Corsini N, Topping D, Morell M, Mohr P. Motivations for avoiding wheat consumption in Australia: results from a population survey. Public Health Nutr 2015;18:490-9.
6. Catassi C, Elli L, Bonaz B, Bouma G, Carroccio A, Castillejo G, et al. Diagnosis of Non-Celiac Gluten Sensitivity (NCGS): The Salerno Experts' Criteria. Nutrients 2015;7:4966-77.
7. Elli L, Tomba C, Branchi F, Roncoroni L, Lombardo V, Bardella MT, et al. Evidence for the Presence of Non-Celiac Gluten Sensitivity in Patients with Functional Gastrointestinal Symptoms: Results from a Multicenter Randomized Double-Blind Placebo-Controlled Gluten Challenge. Nutrients 2016;8:84.
8. Volta U, Tovoli F, Cicola R, Parisi C, Fabbri A, Piscaglia M, et al. Serological tests in gluten sensitivity (nonceliac gluten intolerance). J Clin Gastroenterol 2012;46:680-5.
9. Volta U, Bardella MT, Calabrò A, Troncone R, Corazza GR. An Italian prospective multicenter survey on patients suspected of having non-celiac gluten sensitivity. BMC Med 2014;12:85.
10. Carroccio A, Mansueto P, Iacono G, Soresi M, D'Alcamo A, Cavataio F, et al. Non-celiac gluten sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol 2012;107:1898-906.
11. Caio G, Volta U, Tovoli F, De Giorgio R. Effect of gluten free diet on immune response to gliadin in patients with non-celiac gluten sensitivity. BMC Gastroenterol 2014;14:26.
12. Francavilla R, Cristofori F, Castellaneta S, Polloni C, Albano V, Dellatte S, et al. Clinical, serologic, and histologic features of gluten sensitivity in children. J Pediatr 2014;164:463-7.e1.
13. Uhde M, Ajamian M, Caio G, De Giorgio R, Indart A, Green PH, et al. Intestinal cell damage and systemic immune activation in individuals reporting sensitivity to wheat in the absence of coeliac disease. Gut 2016;65:1930-7.
14. Sapone A, Lammers KM, Casolaro V, Cammarota M, Giuliano MT, De Rosa M, et al. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med 2011;9:23.
15. Sapone A, Lammers KM, Mazzarella G, Mikhailenko I, Carteni M, Casolaro V, et al. Differential mucosal IL-17 expression in two gliadin-induced disorders: gluten sensitivity and the autoimmune enteropathy celiac disease. Int Arch Allergy Immunol 2010;152:75-80.
16. Picarelli A, Borghini R, Di Tola M, Marino M, Urciuoli C, Isonne C, et al. Intestinal, Systemic, and Oral Gluten-related Alterations in Patients With Nonceliac Gluten Sensitivity. J Clin Gastroenterol 2016;50:849-58.

Table 1. Advantages and disadvantages of currently available diagnostic potential investigations for non celiac gluten sensitivity.

| Diagnostic method                                      | Advantages                                                                 | Disadvantages                                                                 |
|---------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|
| Serology                                                | • The test is easily available in laboratories                             | • Low diagnostic power (positivity in only the 50%)                           |
|                                                        | • Data from literature show high agreement                                  |                                                                                |
| Cytokine assay                                          | • Highly standardized technique                                             | • Conflicting result                                                          |
|                                                        | • High specificity                                                          | • Low sensitivity                                                             |
|                                                        |                                                                             | • Available only for research purposes                                        |
| Histopathology and immunohistochemistry                 | • The test is easily available in laboratories                             | • Very few studies in literature                                              |
|                                                        | • Excellent sensitivity and specificity                                      |                                                                                |
| Permeability test                                       | • Highly standardized technique                                             | • Low sensitivity                                                             |
|                                                        |                                                                             | • Conflicting results                                                         |
|                                                        | • High consensus level                                                      | • Long duration time                                                          |
| Double blind placebo controlled oral provocation test   |                                                                             |                                                                                |
| (Salerno criteria)                                      | • High sensitivity and specificity                                          |                                                                                |
208 Biological markers for non-celiac gluten sensitivity

17. Losurdo G, Giorgio F, Piscitelli D, Montenegro L, Covelli C, Fiore MG, et al. May the assessment of baseline mucosal molecular pattern predict the development of gluten related disorders among microscopic enteritis? World J Gastroenterol 2016;22:8017-25.

18. Di Sabatino A, Giuffrida P, Fornasa G, Salvatore C, Vanoli A, Naviglio S, et al. Innate and adaptive immunity in self-reported nonceliac gluten sensitivity versus celiac disease. Dig Liver Dis 2016;48:745-52.

19. Brottveit M, Beitnes AC, Tollefsen S, Bratlie JE, Jahnsen FL, Johansen FE, et al. Mucosal cytokine response after short-term gluten challenge in celiac disease and non-celiac gluten sensitivity. Am J Gastroenterol 2013;108:842-50.

20. Bucci C, Zingone F, Russo I, Morra I, Tortora R, Pogna N, et al. Gliadin does not induce mucosal inflammation or basophil activation in patients with nonceliac gluten sensitivity. Clin Gastroenterol Hepatol 2013;11:1294-9.e1.

21. Valeri MC, Ricci C, Spisni E, Di Silvestro R, De Fazio L, Cavazza E, et al. Responses of peripheral blood mononucleated cells from non-celiac gluten sensitive patients to various cereal sources. Food Chem 2015;176:167-74.

22. Alvisi P, De Fazio L, Valeri MC, Cavazza E, Salerno A, Lacorte D, et al. Responses of blood mononucleated cells and clinical outcome of non-celiac gluten sensitive pediatric patients to various cereal sources: a pilot study. Int J Food Sci Nutr 2017;68:1005-12.

23. Ierardi E, Losurdo G, Iannone A, Piscitelli D, Amoruso A, Barone M, et al. Lymphocytic duodenitis or microscopic enteritis and gluten-related conditions: what needs to be explored? Ann Gastroenterol 2017;30:380-392.

24. Rostami K, Aldulaimi D, Holmes G, Johnson MW, Robert M, Srivastava A, et al. Microscopic enteritis: Bucharest consensus. World J Gastroenterol 2015;21:2593-604.

25. Losurdo G, Piscitelli D, Giangaspero A, Principi M, Buffelli F, Giorgio F, et al. Evolution of nonspecific duodenal lymphocytosis over 2 years of follow-up. World J Gastroenterol 2015;21:7545-52.

26. Villanacci V, Lanzini A, Lanzarotto F, Ricci C. Observations on the paper of Carroccio et al. "non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity". Am J Gastroenterol 2013;108:619-20.

27. Losurdo G, Piscitelli D, Pezzuto F, Fortarezza F, Covelli C, Marra A, et al. T Helper Lymphocyte and Mast Cell Immunohistochemical Pattern in Nonceliac Gluten Sensitivity. Gastroenterol Res Pract 2017;2017:5023680.

28. D’Alcamo A, Mansueto P, Soresi M, Iacobucci R, Blasca F, Geraci G, et al. Contact Dermatitis Due to Nickel Allergy in Patients Suffering from Non-Celiac Wheat Sensitivity. Nutrients 2017;9:E103.

29. Carroccio A, Mansueto P, D’Alcamo A, Iacono G. Non-celiac wheat sensitivity as an allergic condition: personal experience and narrative review. Am J Gastroenterol 2013;108:1845-52.

30. Frossi B, Tripodo C, Guarnotta C, Carroccio A, De Carli M, De Carli S, et al. Mast cells are associated with the onset and progression of celiac disease. J Allergy Clin Immunol 2017;139:1266-74.e1.

31. Di Liberto D, Mansueto P, D’Alcamo A, Lo Pizzo M, Lo Presti E, Geraci G, et al. Predominance of Type 1 Innate Lymphoid Cells in the Rectal Mucosa of Patients With Non-Celiac Wheat Sensitivity: Reversal After a Wheat-Free Diet. Clin Transl Gastroenterol 2016;7:e178.

32. Johnston SD, Smye M, Watson RP. Intestinal permeability tests in coeliac disease. Clin Lab 2001;47:143-50.

33. Hollon J, Puppa EL, Greenwald B, Goldberg E, Guerrerio A, Fasano A. Effect of gliadin on permeability of intestinal biopsy explants from celiac disease patients and patients with non-celiac gluten sensitivity. Nutrients 2015;7:1565-76.

34. Ierardi E, Losurdo G, Piscitelli D, Giorgio F, Sorrentino C, Principi M, et al. Seronegative celiac disease: where is the specific setting? Gastroenterol Hepatol Bed Bench 2015;8:110-6.

35. Ierardi E, Amoruso A, Giorgio F, Principi M, Losurdo G, Piscitelli D, et al. Mucosal molecular pattern of tissue transglutaminase and interferon gamma in suspected seronegative celiac disease at marsh 1 and 0 stages. Saudi J Gastroenterol 2015;21:379-85.